NasdaqGS:RIGLBiotechs
Rigel Pharmaceuticals (RIGL) Turns Profitable, But Guidance for Earnings Decline Challenges Bullish Narratives
Rigel Pharmaceuticals (RIGL) has turned profitable in the last year, with net profits reversing after a string of losses. The company’s earnings grew at an impressive 40.2% per year over the past five years, signaling high quality performance. However, forward guidance calls for a 4% annual decline in earnings over the next three years and revenue growth of just 6.5% per year, falling short of the US market’s 10.5% average. Despite upbeat profit growth, the outlook now turns on whether Rigel...